General information

Selecting medicine

The practice of medicine has always been about treating each patient individually, and clinicians have long observed that patients may respond differently to medication.

The task of getting the right treatment for a patient has been quite challenging – see below: “The estimated percentage of non-responders”.

However, developments in science and technology have made it possible to select the right treatment using a gene based decision support tool to predict which specific medical treatment a patient should have.

The science of pharmacogenomics is the study of the effect of our genetic variation on our response to a drug. The technology combines the science of drugs and genomics (the study og genes and functions) and is capturing how to personalize and improve medical treatment.

Personal Medicine™ Profile is such a decision support tool helping customers and doctors selecting and adjusting medical treatment.

“The right medication for the right person, in the right dose”

Personal Medicine Profile™

  • An advanced drug response test covering more than 200 of the most frequent prescriptions within heart, pain, rheumatism, gastroenterology, mental health, multiple diseases, cancer and lifestyle

  • Free updates of your report for new medication information and dosage recommendations

  • You have access to your result day and night -> share it with your doctor or pharmacy

  • Several insurance companies help cover the cost

Order Now

PMP is a once only investment. Use it when new medicine is prescribed.

We take good care of your personal data according to GDPR (EU) with our Security by Design set-up.

Get your Personal Medicine Profile here

Read more about: GDPRPrivacy policyData SafetyQuality Policy

Estimated percentage of non-responders to a certain drug treatment

 

38%

DEPRESSION

40%

ASTHMA

43%

DIABETES

50%

ARTHRITIS

70%

ALZHEIMER’S

75%

CANCER

Source: Brian B. Spear. Mango Heath-Chiozzi. Jeffery Huff. “Clinical Trends in Molecular Medicine” Volume 7, issue 5, 1. May 2001, pages 201-204

Regulatory

The Center for Drug Evaluation and Research (CDER) of the US FDA has supported the use of pharmacogenomics for more than a decade by providing regulatory advice, renewing applications and developing policies and processes focused on genomics and individualized therapeutics.

In February 2020, the FDA published a list of 107 active drug constituents with “actional guidelines” recommending a pharmacogenomic test due to the frequent polymorphism in essential genes.

The European Medicines Agency supports the use of Personalized Medicine and requires pharmacogenomic data when new medicines are registered. However, their recommendations of pharmacogenomic testing related to drug treatment are reluctant.

For example, the prescription of fluorouracil for oncology patients is covered by an EMA recommendation: https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal

In summary, the US and European authorities support the use of pharmacogenomic testing to some extent before prescribing particular medicines where genetic polymorphism plays an important role.

Four simple and easy steps

Personal Medicine Profile
Get your Personal Medicine Profile

The Personal Medicine Profile consists of three steps:


1. Your Personal Genotype sequencing from our laboratory
2. Your bioinformatics built on international scientific research
3. Your PMP report, a decision support tool used to optimize your medication

Trusted Partners

Genetelligence focus on services, research and development in the field of personalized medicine. Therefore, we work with a wide range of private and public institutions. Please, feel free to contact us for possible cooperation.

Get your own Personal Medicine Profile now